3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Venous Thromboembolism
10
Pulmonary Embolism
4
Venous Thrombosis
3
Neoplasms
3
Thrombosis
2
Multiple Myeloma
2
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Embolism
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Cyclophosphamide
61
Rituximab
50
fludarabine
34
Prednisone
33
Doxorubicin
28
Biopsy
26
Vincristine
25
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
16
Lenalidomide
16
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
apixaban
×
1 year
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled